JP6898336B2 - Ｔｌｒ７アゴニストのマレイン酸塩、その結晶形ｃ、ｄ及びｅ、マレイン酸塩及び結晶形の調製方法及び使用 - Google Patents

Ｔｌｒ７アゴニストのマレイン酸塩、その結晶形ｃ、ｄ及びｅ、マレイン酸塩及び結晶形の調製方法及び使用 Download PDF

Info

Publication number
JP6898336B2
JP6898336B2 JP2018540750A JP2018540750A JP6898336B2 JP 6898336 B2 JP6898336 B2 JP 6898336B2 JP 2018540750 A JP2018540750 A JP 2018540750A JP 2018540750 A JP2018540750 A JP 2018540750A JP 6898336 B2 JP6898336 B2 JP 6898336B2
Authority
JP
Japan
Prior art keywords
crystal
crystalline
formula
crystalline form
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018540750A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019505532A5 (2
JP2019505532A (ja
Inventor
ディン，ツァオジョン
スン，フェイ
フゥー，インフゥー
シュウ，イーロン
ワン，チェン
ヤン，リン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of JP2019505532A publication Critical patent/JP2019505532A/ja
Publication of JP2019505532A5 publication Critical patent/JP2019505532A5/ja
Application granted granted Critical
Publication of JP6898336B2 publication Critical patent/JP6898336B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2018540750A 2016-02-05 2017-02-04 Ｔｌｒ７アゴニストのマレイン酸塩、その結晶形ｃ、ｄ及びｅ、マレイン酸塩及び結晶形の調製方法及び使用 Active JP6898336B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610082030.0 2016-02-05
CN201610082030.0A CN107043380A (zh) 2016-02-05 2016-02-05 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途
PCT/CN2017/072890 WO2017133683A1 (zh) 2016-02-05 2017-02-04 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e及其制备方法和用途

Publications (3)

Publication Number Publication Date
JP2019505532A JP2019505532A (ja) 2019-02-28
JP2019505532A5 JP2019505532A5 (2) 2020-02-27
JP6898336B2 true JP6898336B2 (ja) 2021-07-07

Family

ID=59500111

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018540750A Active JP6898336B2 (ja) 2016-02-05 2017-02-04 Ｔｌｒ７アゴニストのマレイン酸塩、その結晶形ｃ、ｄ及びｅ、マレイン酸塩及び結晶形の調製方法及び使用

Country Status (23)

Country Link
US (2) US10780091B2 (2)
EP (1) EP3412671B1 (2)
JP (1) JP6898336B2 (2)
KR (1) KR102393279B1 (2)
CN (2) CN107043380A (2)
AR (1) AR107547A1 (2)
AU (1) AU2017215800B2 (2)
CA (1) CA3013682C (2)
CL (1) CL2018002089A1 (2)
DK (1) DK3412671T3 (2)
EA (1) EA038794B1 (2)
ES (1) ES2834303T3 (2)
HU (1) HUE052211T2 (2)
IL (1) IL260965B (2)
MX (1) MX374295B (2)
MY (1) MY196762A (2)
NZ (1) NZ745231A (2)
PH (1) PH12018501644B1 (2)
SG (1) SG11201806682TA (2)
TW (1) TWI778951B (2)
UA (1) UA123781C2 (2)
WO (1) WO2017133683A1 (2)
ZA (1) ZA201805185B (2)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107043378A (zh) * 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种吡咯并[3,2-d]嘧啶类化合物的制备方法及其中间体
CN107043379A (zh) 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的晶型a、其制备方法和医药用途
CN107043380A (zh) 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途
AU2019272478B2 (en) * 2018-05-25 2024-06-06 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. TLR7 agonist and pharmaceutical combination thereof for treating lung cancer
WO2020162705A1 (ko) 2019-02-08 2020-08-13 성균관대학교산학협력단 톨-유사 수용체 7 또는 8 작용자와 콜레스테롤의 결합체 및 그 용도
CA3170551A1 (en) 2020-03-02 2021-09-10 Yong Taik Lim Live-pathogen-mimetic nanoparticles based on pathogen cell wall skeleton, and production method thereof
US20230277525A1 (en) 2020-08-04 2023-09-07 Progeneer Inc Conjugate of functional drug and toll-like receptor 7 or 8 agonist of which active site is temporarily inactivated and use thereof
JP7690221B2 (ja) 2020-08-04 2025-06-10 プロジェニア インコーポレイテッド 動力学的に作用するアジュバントアンサンブル
US20230346924A1 (en) 2020-08-04 2023-11-02 Progeneer Inc. Mrna vaccine comprising adjuvant capable of kinetic control

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3376479B2 (ja) * 1991-08-12 2003-02-10 武田薬品工業株式会社 縮合ピリミジン誘導体、その製造法および用途
ES2232871T3 (es) 1996-07-03 2005-06-01 Sumitomo Pharmaceuticals Company, Limited Nuevos derivados de purina.
DE69817393T2 (de) 1997-11-28 2004-06-17 Sumitomo Pharmaceuticals Co., Ltd. Neue heterozyklische verbindungen
CN101304748A (zh) 2005-08-22 2008-11-12 加利福尼亚大学董事会 Tlr激动剂
CA2691444C (en) 2007-06-29 2016-06-14 Gilead Sciences, Inc. Purine derivatives and their use as modulators of toll-like receptor 7
ES2359123T3 (es) 2007-08-03 2011-05-18 Pfizer Limited Imidazopiridinonas.
RS53347B (sr) 2008-12-09 2014-10-31 Gilead Sciences, Inc. Modulatori toll-sličnih receptora
WO2012106522A2 (en) 2011-02-04 2012-08-09 Duquesne University Of The Holy Spirit Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient
EP2800569B1 (en) 2012-01-05 2018-07-25 Northeastern University Allosteric modulators of cb1 cannabinoid receptors
DK2906563T3 (en) 2012-10-10 2018-06-06 Janssen Sciences Ireland Uc PYRROLO [3,2-D] PYRIMIDINE DERIVATIVES FOR TREATING VIRUS INFECTIONS AND OTHER DISEASES
AU2013348217B2 (en) * 2012-11-20 2016-10-06 Glaxosmithkline Llc Novel compounds
BR112015011439A2 (pt) 2012-11-20 2017-07-11 Glaxosmithkline Llc composto, composição farmacêutica, composição de vacina, e, uso de um composto
EA028480B1 (ru) 2012-11-20 2017-11-30 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Новые соединения
KR20160124157A (ko) 2014-02-20 2016-10-26 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 인간 인터페론의 유도인자로서의 피롤로[3,2]피리미딘 유도체
ES2908150T3 (es) 2014-05-01 2022-04-27 Novartis Ag Compuestos y composiciones como agonistas del receptor de tipo Toll 7
PL3137470T3 (pl) * 2014-05-01 2021-10-11 Novartis Ag Związki i kompozycje jako agonisty receptora toll-like 7
HRP20210927T1 (hr) * 2014-08-15 2021-09-03 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Spojevi pirolopirimidina koje se koriste kao agonist tlr7
CN105367576A (zh) * 2014-08-15 2016-03-02 正大天晴药业集团股份有限公司 作为tlr7激动剂的吡咯并嘧啶化合物
CN105732635A (zh) 2014-12-29 2016-07-06 南京明德新药研发股份有限公司 一类Toll样受体7激动剂
MX2018005388A (es) 2015-11-05 2018-08-16 Basf Se Oxadiazoles sustituidos para combatir hongos fitopatogenos.
UA121345C2 (uk) 2015-11-05 2020-05-12 Чіа Тай Тяньцин Фармасьютікал Груп Ко., Лтд. 7-(тіазол-5-іл)піролопіримідин як агоніст рецептора tlr7
TWI714661B (zh) 2015-11-05 2021-01-01 法商賽諾菲公司 新穎念珠藻素化合物及接合物、其製備與其治療用途
CN107043380A (zh) 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途
CN107043379A (zh) 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的晶型a、其制备方法和医药用途
CN107043377A (zh) 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的三氟乙酸盐、晶型b及其制备方法、药物组合物和用途
CN107043378A (zh) * 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种吡咯并[3,2-d]嘧啶类化合物的制备方法及其中间体

Also Published As

Publication number Publication date
HK1259175A1 (zh) 2019-11-29
AU2017215800B2 (en) 2020-08-20
CA3013682A1 (en) 2017-08-10
UA123781C2 (uk) 2021-06-02
AU2017215800A1 (en) 2018-08-30
ZA201805185B (en) 2024-08-28
NZ745231A (en) 2022-07-29
SG11201806682TA (en) 2018-09-27
EP3412671A1 (en) 2018-12-12
MX2018009500A (es) 2018-12-11
JP2019505532A (ja) 2019-02-28
CA3013682C (en) 2022-06-21
US20200368241A1 (en) 2020-11-26
ES2834303T3 (es) 2021-06-17
US10780091B2 (en) 2020-09-22
CL2018002089A1 (es) 2018-12-07
PH12018501644A1 (en) 2019-06-03
CN108602830A (zh) 2018-09-28
TWI778951B (zh) 2022-10-01
EA038794B1 (ru) 2021-10-20
DK3412671T3 (da) 2020-11-09
MY196762A (en) 2023-05-03
MX374295B (es) 2025-03-06
EA201891770A1 (ru) 2019-01-31
US20190070179A1 (en) 2019-03-07
PH12018501644B1 (en) 2022-09-07
BR112018015881A2 (pt) 2018-12-26
AR107547A1 (es) 2018-05-09
IL260965B (en) 2022-02-01
CN107043380A (zh) 2017-08-15
KR20180104116A (ko) 2018-09-19
HUE052211T2 (hu) 2021-04-28
KR102393279B1 (ko) 2022-05-02
TW201728588A (zh) 2017-08-16
WO2017133683A1 (zh) 2017-08-10
CN108602830B (zh) 2020-07-28
EP3412671A4 (en) 2019-07-24
EP3412671B1 (en) 2020-09-16

Similar Documents

Publication Publication Date Title
JP6889171B2 (ja) Ｔｌｒ７アゴニスト結晶形ａ、その調製方法及び使用
JP6877450B2 (ja) Ｔｌｒ７アゴニストのトリフルオロ酢酸塩及びその結晶形ｂ、調製方法、並びに使用
JP6898336B2 (ja) Ｔｌｒ７アゴニストのマレイン酸塩、その結晶形ｃ、ｄ及びｅ、マレイン酸塩及び結晶形の調製方法及び使用
HK1259175B (zh) 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e及其制备方法和用途
HK1259170B (zh) 一种tlr7激动剂的晶型a、其制备方法和用途
HK1259182B (zh) 一种tlr7激动剂的三氟乙酸盐、晶型b、制备方法和用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200120

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200120

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20201126

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210226

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210518

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210610

R150 Certificate of patent or registration of utility model

Ref document number: 6898336

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250